As reported in our work, we examined the aberrant expression of FEZF1-AS1, its association with clinicopathological characteristics and patients’ prognosis, its regulatory mechanisms on ZNF312B, and its biological effects on PC in vitro and in vivo. This evidence concerns the gene FEZF1 and pachyonychia congenita.